Pacira Pharmaceuticals(PCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PCRX Pacira Pharmaceuticals

Trading 04-24 12:41:31 EDT

24.37

-0.99

-3.90%

High25.43	Low24.37	Vol194.99K
Open25.39	D1 Closing25.36	Amplitude4.16%
Mkt Cap986.74M	Tradable Cap899.15M	Total Shares40.49M
T/O4.85M	T/O Rate0.53%	Tradable Shares36.90M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PCRX","market":"US","secType":"STK","nameCN":"Pacira Pharmaceuticals","latestPrice":24.37,"timestamp":1777048875850,"preClose":25.36,"halted":0,"volume":194990,"delay":0,"changeRate":-0.03903785488958984,"floatShares":36895900,"shares":40489894,"eps":0.157833,"marketStatus":"Trading","change":-0.99,"latestTime":"04-24 12:41:31 EDT","open":25.39,"high":25.425,"low":24.37,"amount":4854687.86888,"amplitude":0.041601,"askPrice":24.41,"askSize":12,"bidPrice":24.38,"bidSize":4,"shortable":3,"etf":0,"ttmEps":0.157833,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1777060800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1296709200000,"exchange":"NASDAQ","adjPreClose":25.36,"preHourTrading":{"tag":"盘前","latestPrice":25.15,"preClose":25.36,"latestTime":"08:27 EDT","volume":256,"amount":6497.659136,"timestamp":1777033633620,"change":-0.21,"changeRate":-0.008281,"amplitude":0.023659},"postHourTrading":{"tag":"盘后","latestPrice":25.36,"preClose":25.36,"latestTime":"16:10 EDT","volume":29474,"amount":747460.64,"timestamp":1776975004425,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.763662,"impliedVol":0.6412,"impliedVolPercentile":0.9044},"requestUrl":"/m/hq/s/PCRX/wiki","defaultTab":"wiki","newsList":[{"id":"1161112112","title":"Earning Preview: Pacira Pharmaceuticals this quarter’s revenue is expected to decrease by 1.35%, and institutional views are bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1161112112","media":"Earnings Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1161112112?lang=en_us&edition=fundamental","pubTime":"2026-04-24 01:39","pubTimestamp":1776965996,"startTime":"0","endTime":"0","summary":"Abstract Pacira Pharmaceuticals will report quarterly results on April 30, 2026 Post Market; this preview consolidates last quarter’s outcomes and the latest consensus for revenue, EBIT, and EPS...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Earning Preview: Pacira Pharmaceuticals this quarter’s revenue is expected to decrease by 1.35%, and institutional views are bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629907481","title":"Pacira CFO Shawn Cross disposes 12,059 common shares for $303,299.99","url":"https://stock-news.laohu8.com/highlight/detail?id=2629907481","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629907481?lang=en_us&edition=fundamental","pubTime":"2026-04-23 08:03","pubTimestamp":1776902636,"startTime":"0","endTime":"0","summary":"Pacira BioSciences CFO Shawn Cross sold 12,059 shares in transactions dated April 20-22.Sales were priced at USD 25.14 per share on April 20, USD 25.01 per share on April 21-22.Cross exercised stock options for 12,059 shares at USD 16.45 per share over same period.Directly held common stock position was 105,341 shares following transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 22, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL5f1Bv5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Pacira CFO Shawn Cross disposes 12,059 common shares for $303,299.99","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629774211","title":"A Look At Pacira BioSciences (PCRX) Valuation After New EXPAREL Health Economic Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2629774211","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629774211?lang=en_us&edition=fundamental","pubTime":"2026-04-21 04:09","pubTimestamp":1776715796,"startTime":"0","endTime":"0","summary":"Pacira BioSciences (PCRX) shares recently reacted to fresh health economic data on its flagship non opioid pain drug, EXPAREL, following presentations at the Academy of Managed Care Pharmacy Annual 2026 Meeting in Nashville.\nSee our latest analysis for Pacira BioSciences.\nThe new EXPAREL health economic data arrives alongside a 90 day share price return of 28.08% and a 30 day share price return of 11.80%. However, the 1 year total shareholder return of 4.56% and 5 year total shareholder...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/a-look-at-pacira-biosciences-pcrx-valuation-after-new-expare","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/a-look-at-pacira-biosciences-pcrx-valuation-after-new-expare","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PCRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628174689","title":"H.C. Wainwright Reaffirms Their Buy Rating on Pacira Pharmaceuticals (PCRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2628174689","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628174689?lang=en_us&edition=fundamental","pubTime":"2026-04-20 17:16","pubTimestamp":1776676562,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Pacira Pharmaceuticals today and set a price target of $38.00. According to TipRank...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-pacira-pharmaceuticals-pcrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-pacira-pharmaceuticals-pcrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627290295","title":"Pacira to report first-quarter results after market close, host conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2627290295","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627290295?lang=en_us&edition=fundamental","pubTime":"2026-04-16 20:07","pubTimestamp":1776341278,"startTime":"0","endTime":"0","summary":"Pacira Biosciences will report first-quarter fiscal 2026 financial results on April 30, 2026.Management will host conference call plus webcast at 4:30 p.m. ET on April 30, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief on April 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL5yDqtH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627841458","title":"Pacira real-world study shows EXPAREL lowers costs in outpatient hip replacements","url":"https://stock-news.laohu8.com/highlight/detail?id=2627841458","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627841458?lang=en_us&edition=fundamental","pubTime":"2026-04-13 20:05","pubTimestamp":1776081944,"startTime":"0","endTime":"0","summary":"Pacira presented real-world study results at AMCP Annual 2026 Meeting on April 13 showing EXPAREL use in outpatient hip or knee replacement was tied to lower or comparable total healthcare costs versus non-liposomal regimens.Analysis in Medicare Advantage outpatient total hip arthroplasty linked EXPAREL to lower post-surgery costs over 3 months and 6 months, with reduced opioid use in patients with low back pain.Separate outpatient total knee arthroplasty cohort showed EXPAREL generally tracked with lower adjusted costs, with clearer savings in teaching-hospital settings.Three-year payer budget impact model in commercial and Medicare Advantage outpatient knee replacement projected net savings of USD 117,868 per 1 million members by year 3 versus ropivacaine, as higher drug acquisition costs were offset by lower overall care spending.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL7C9LdM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","BK4588","IE00BKPKM429.USD","LU0314104364.USD","SG9999014013.SGD","LU2095319765.USD","BK4585","PCRX","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","BK4007","LU2210149790.SGD","SG9999014005.SGD","NDAQ","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","BK4112","SG9999014039.USD","LU2210150020.SGD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625124946","title":"Pacira to join Needham Virtual Healthcare Conference fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2625124946","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625124946?lang=en_us&edition=fundamental","pubTime":"2026-04-08 20:04","pubTimestamp":1775649862,"startTime":"0","endTime":"0","summary":"Pacira BioSciences will join an analyst-led fireside chat at 25th Annual Needham Virtual Healthcare Conference on April 15, 2026 at 9:30 a.m. ET.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief on April 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL3bGJqK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625946950","title":"Pacira grants inducement equity awards to new hires, sets options exercise price at $22.7","url":"https://stock-news.laohu8.com/highlight/detail?id=2625946950","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625946950?lang=en_us&edition=fundamental","pubTime":"2026-04-08 20:02","pubTimestamp":1775649752,"startTime":"0","endTime":"0","summary":"Pacira granted inducement equity awards on April 2, 2026 under its amended and restated 2014 Inducement Plan.Two new employees received stock options covering 5,000 shares, priced at USD 22.70 per share with a 10-year term.Option vesting starts with 25% on first anniversary of employment, then quarterly over next 36 months.Seven new employees received restricted stock units covering 13,000 shares, vesting annually in four equal installments starting April 1, 2027.Equity awards vest only while recipients remain employed.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL1PsvhM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","BK4585","IE00BGHQF748.EUR","SG9999014013.SGD","SG9999014021.USD","IE00BN0W2W23.USD","IE00BKPKM429.USD","SG9999014005.SGD","LU0314104364.USD","BK4112","SG9999014039.USD","BK4588","LU2210149790.SGD","LU2095319765.USD","IE00BN0W2T93.GBP","PCRX","IE00BN0W2V16.EUR","LU2210150020.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623173613","title":"Pacira says EXPAREL lowers total cost of care in real-world orthopedic studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2623173613","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623173613?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:05","pubTimestamp":1774872305,"startTime":"0","endTime":"0","summary":"Pacira outlined real-world studies on EXPAREL showing lower total cost of care in total knee arthroplasty and spinal fusion, with results scheduled for presentation at Orthopaedic Research Society 2026 Annual Meeting on March 30.In outpatient total knee arthroplasty, liposomal bupivacaine reduced total costs versus ropivacaine by about USD 1.4 thousand in Medicare Advantage patients.In inpatient spinal fusion, liposomal bupivacaine cut mean total costs by about USD 6 thousand versus non-liposomal regimens in a commercial cohort.Spinal fusion analysis linked savings mainly to shorter length of stay, down 1.83 days.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL7pS9lw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","SG9999014005.SGD","SG9999014021.USD","LU2095319765.USD","NDAQ","BK4585","IE00BGHQF748.EUR","LU0314104364.USD","LU2210149790.SGD","BK4588","LU2210150020.SGD","SG9999014013.SGD","BK4007","IE00BN0W2W23.USD","PCRX","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","BK4112","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622868859","title":"Pacira BioSciences Is Maintained at Equal-Weight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2622868859","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622868859?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:56","pubTimestamp":1774529760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PCRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2026 08:56 ET (12:56 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620973395","title":"J.P. Morgan Sticks to Their Sell Rating for Pacira Pharmaceuticals (PCRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620973395","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620973395?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:59","pubTimestamp":1774007976,"startTime":"0","endTime":"0","summary":"In a report released today, Hardik Parikh from J.P. Morgan maintained a Sell rating on Pacira Pharmaceuticals, with a price target of $23.00. Accor...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-sticks-to-their-sell-rating-for-pacira-pharmaceuticals-pcrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-sticks-to-their-sell-rating-for-pacira-pharmaceuticals-pcrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620745662","title":"Pacira BioSciences Chief Medical Officer Jonathan Slonin disposes of USD 74,411 in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620745662","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620745662?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:43","pubTimestamp":1773956619,"startTime":"0","endTime":"0","summary":"Pacira reported a change in beneficial ownership by Jonathan Slonin, Chief Medical Officer.On 03/17/2026, Slonin sold 3,261 shares of common stock at USD 22.82 per share.Following the transaction, he beneficially owned 223,640.18 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 19, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDLZ3v4Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Pacira BioSciences Chief Medical Officer Jonathan Slonin disposes of USD 74,411 in common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620427456","title":"Pacira BioSciences Director Mark Froimson Disposes of USD 10,905 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620427456","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620427456?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:43","pubTimestamp":1773956617,"startTime":"0","endTime":"0","summary":"Pacira reported that director Mark Froimson sold 500 shares of common stock on March 17, 2026.The shares were sold at USD 21.81 per share.Following the transaction, Froimson beneficially owned 20,136 shares directly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 19, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL7d6H06:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Pacira BioSciences Director Mark Froimson Disposes of USD 10,905 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619777158","title":"BUZZ-U.S. STOCKS ON THE MOVE  -Natera, Pacira BioSciences, Kezar Life Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2619777158","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619777158?lang=en_us&edition=fundamental","pubTime":"2026-03-12 23:59","pubTimestamp":1773331150,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE  -Natera, Pacira BioSciences, Kezar Life SciencesWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning Ne","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nL6N40014H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0175139822.USD","AALG","KZR","MELI","KMLI","SM","CE","TBBK","LU0320765646.SGD","CF","CASH","GYRE","LU1116320737.USD","GIII","RPID","XOMO","ARES","NOG","UAL","LU1868837565.USD","LUV","PCRX","MOS","GFS","DOW","JBL","SPRC","BBW","DG","WLTH","XOMZ","BK4121","DKS","SG9999014906.USD","NTRA","CUBI","BX","KKR","MUR","INTS","AAL","BMBL","IE0002270589.USD","SG9999014898.SGD","DAL","OWL","XOMX"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2618313469","title":"Doma Perpetual: Asserts Frank Lee Should Be Replaced Immediately; Pacira Biosciences Board Should Name Interim CEO & Conduct Formal Sale Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2618313469","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618313469?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:20","pubTimestamp":1773318000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nTUA6XQ6NC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PCRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618597999","title":"Pacira BioSciences to Review Activist Investor's Proposed Board Nominees","url":"https://stock-news.laohu8.com/highlight/detail?id=2618597999","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618597999?lang=en_us&edition=fundamental","pubTime":"2026-03-12 05:43","pubTimestamp":1773265380,"startTime":"0","endTime":"0","summary":"Pacira BioSciences said its board would review the nominees proposed by activist investor Doma Perpetual Capital Management.Pacira confirmed Wednesday that Doma nominated three director candidates to stand for election to its board at its annual meeting of shareholders.Doma had said earlier Wednesday its nominees include Christopher Dennis, a physician executive and board-certified psychiatrist; Oliver Benton Curtis III, a former federal prosecutor and trial lawyer; and Eric de Armas, Doma's finance chief and chief compliance officer.Pacira said it has met with Doma 12 times since Frank Lee became its chief executive officer in 2024. It said Doma has not provided new insights regarding Pacira's strategy that it has not already evaluated or executed.Doma said Pacira has underserved its shareholders by raising management compensation and recording higher expenses as the stock has declined. Doma also called for the replacement of Pacira's CEO.Pacira said its plans have the backing of its ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618922534","title":"BUZZ-Pacira rises as DOMA pushes for CEO ouster, board shake-up and sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2618922534","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618922534?lang=en_us&edition=fundamental","pubTime":"2026-03-12 01:19","pubTimestamp":1773249559,"startTime":"0","endTime":"0","summary":"BUZZ-Pacira rises as DOMA pushes for CEO ouster, board shake-up and sale** Shares of drugmaker Pacira BioSciences PCRX.O rise 2% to $22.78 premarket** Activist investor DOMA Perpetual says it has nominated three directors to PCRX board and is seeking the removal of CEO Frank Lee, citing years of poor financial performance** Says Pacira’s stock has fallen 56% over 10 years, 68% over five years and 30% during Lee’s tenure** Adds Pacira is too small to effectively market its non-opioid surgery pain drug Exparel and urges a formal sale process** Criticizes PCRX board for approving high executive pay and moving headquarters to San Francisco** Shares rose ~37% in 2025","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nL4N3ZZ1U7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","00950","BK4007","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618922600","title":"Doma Perpetual nominates three to Pacira board","url":"https://stock-news.laohu8.com/highlight/detail?id=2618922600","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618922600?lang=en_us&edition=fundamental","pubTime":"2026-03-12 01:10","pubTimestamp":1773249023,"startTime":"0","endTime":"0","summary":"Doma Perpetual Capital Management, which owns 7.1% of Pacira’s (PCRX) outstanding shares, announced its nomination of three director candidates to ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/doma-perpetual-nominates-three-to-pacira-board-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/doma-perpetual-nominates-three-to-pacira-board-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PCRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618924799","title":"DOMA Perpetual nominates three directors for Pacira board after taking 7.1% stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2618924799","media":"Reuters","labels":["executive","shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618924799?lang=en_us&edition=fundamental","pubTime":"2026-03-12 01:07","pubTimestamp":1773248825,"startTime":"0","endTime":"0","summary":"DOMA Perpetual, which said it owns about 7.1% of Pacira’s common shares, nominated three director candidates for the board: Christopher Dennis, Oliver Benton Curtis and Eric de Armas. DOMA said the stock is down 56% over the last decade and down 68% over the last five years. It also called for CEO Frank Lee to be replaced and for the board to name an interim CEO. DOMA urged the board to engage bankers and run a sale process for the company.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL7Mh15M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"DOMA Perpetual nominates three directors for Pacira board after taking 7.1% stake","news_tag":"executive,shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618924768","title":"Doma Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira Biosciences, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2618924768","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618924768?lang=en_us&edition=fundamental","pubTime":"2026-03-12 01:06","pubTimestamp":1773248804,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nTUA2PHC4Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PCRX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pacira.com","stockEarnings":[{"period":"1week","weight":0.0629},{"period":"1month","weight":0.0931},{"period":"3month","weight":0.2269},{"period":"6month","weight":0.1665},{"period":"1year","weight":0.0063},{"period":"ytd","weight":-0.0201}],"compareEarnings":[{"period":"1week","weight":0.0097},{"period":"1month","weight":0.0846},{"period":"3month","weight":0.0279},{"period":"6month","weight":0.0461},{"period":"1year","weight":0.3232},{"period":"ytd","weight":0.0389}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.04958},{"month":2,"riseRate":0.666667,"avgChangeRate":0.024537},{"month":3,"riseRate":0.5,"avgChangeRate":-0.00278},{"month":4,"riseRate":0.625,"avgChangeRate":0.045224},{"month":5,"riseRate":0.533333,"avgChangeRate":0.021597},{"month":6,"riseRate":0.4,"avgChangeRate":0.013306},{"month":7,"riseRate":0.4,"avgChangeRate":-0.031855},{"month":8,"riseRate":0.533333,"avgChangeRate":0.016779},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.011519},{"month":10,"riseRate":0.266667,"avgChangeRate":-0.02773},{"month":11,"riseRate":0.733333,"avgChangeRate":0.066003},{"month":12,"riseRate":0.6,"avgChangeRate":0.042036}],"exchange":"NASDAQ","name":"Pacira Pharmaceuticals","nameEN":"Pacira Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pacira Pharmaceuticals(PCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pacira Pharmaceuticals(PCRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pacira Pharmaceuticals,PCRX,Pacira Pharmaceuticals股票,Pacira Pharmaceuticals股票老虎,Pacira Pharmaceuticals股票老虎国际,Pacira Pharmaceuticals行情,Pacira Pharmaceuticals股票行情,Pacira Pharmaceuticals股价,Pacira Pharmaceuticals股市,Pacira Pharmaceuticals股票价格,Pacira Pharmaceuticals股票交易,Pacira Pharmaceuticals股票购买,Pacira Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pacira Pharmaceuticals(PCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pacira Pharmaceuticals(PCRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction